News & Updates

High expression of Wilms’ tumor 1-associating protein (WTAP) in patients with nonsmall cell lung cancer (NSCLC) appears to promote poor clinical outcomes, suggests a study.

In the treatment of patients with rifampicin-resistant tuberculosis (TB), two bedaquiline-containing regimens, namely a 9-month all-oral regimen and a shorter 6-month regimen with 8 weeks of aminoglycoside, maintains superior efficacy to a 9-month injectable regimen through 132 weeks, according to long-term data from the STREAM 2 trial.

Many women with pulmonary arterial hypertension (PAH) with a mild functional impairment suffer from sexual dysfunction, a recent study claims.

Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.

The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

Ileus and pneumonia occur more frequently than previously reported among individuals with schizophrenia treated with clozapine, reveals a recent study, noting that such conditions also contribute to increased mortality.

First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.

Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.